Drew Young appointed senior vice president of neurology and immunology at EMD Serono
EMD Serono, a subsidiary of Germany's Merck KGaA (MRK: DE), has appointed Drew Young as senior vice president of neurology and immunology, where he will lead the strategic direction of the US neurology and immunology franchise. He brings more than 20 years of experience in marketing and sales in pharma and biotech companies, and joins the company from US biotech firm Biogen Idec (Nasdaq: BIIB).
Mr Young's other roles include at Bristol-Myers Squibb in Canada and the US, where he was northeast regional sales director for the company's cardiovascular and metabolic portfolio, and US brand lead for its hypertension portfolio. He has also held positions at Schering Plough Canada and Novartis Canada.
The neurology franchise' lead product is Rebic (interferon beta-1a) for relapsing multiple sclerosis. It is a high-dose, high-frequency interferon that has been proved superior to a low-dose, low-frequency interferon in a clinical trial.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze